Frequency and Clinicohaematological Pattern of Myeloproliferative Neoplasms Among Patients Presenting in Tertiary Care Hospital
DOI:
https://doi.org/10.51273/esc25.251321127Keywords:
myeloproliferative neoplasms, chronic myelogenous leukemia, primary myelofibrosisAbstract
Abstract
Objective: To determine the frequency and Clinico-haemtological pattern of myeloproliferative neoplasms
(MPNs) among patients presenting in a Tertiary Care Hospital of Lahore
Material and Methods: This cross sectional study was conducted on 241 patients presenting in Hematology
Department of Jinnah Hospital Lahore r for bone marrow biopsy after taking approval from IRB. Frequency
of myeloproliferative diseases like Chronic myelogenous leukemia, Polycythemia Vera, Essential
thrombocythemia, Primary Myelofibrosis was determined and main clinical and hematologic patterns
among patients of myeloproliferative neoplasms were noted. Data analysis was done using SPSS. Qualitative
variables were presented as frequency and percentages, quantitative variables were presented as mean and
SD. Data was stratified for age and gender, post stratification chi square was applied and p </= 0.05 was taken
as significant.
Results: In this study, frequency of MPNs in patients presenting for bone marrow biopsy was found to be
31.54%. Frequency of different MPNs in the 241 patients presenting for bone marrow biopsy were as
follows; Chronic myelogenous leukemia was found in 53, Polycythemia Vera in 13, Essential
thrombocythemia in 06 and Primary Myelofibrosis in 04 patients. Frequency of various clinico
hematological patterns shows pallor 82.89%, followed by weight loss 80.26%, fever 73.68%, hepatomegaly
32.89%, splenomegaly 19.18%. bleeding 15.79%, and visual disturbance 14.47%. Among hematological
parameters anemia was present in 69.74% followed by leukocytosis 31.51%, and thrombocytopenia in
21.05%
Conclusion: This study concluded that frequency of myeloproliferative neoplasms in patients presenting for
bone marrow biopsy was 31.54% with chronic myelogenous leukemia being the most common followed by
polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Keywords: Myeloproliferative Neoplasms, Chronic Myelogenous Leukemia, Primary Myelofibrosis.
How to cite: Gul A, Zahid S, Irum S, Ghazanfar M, Kanwal S, Dawood N. Frequency and Clinicohaematological
Pattern of Myeloproliferative Neoplasms Among Patients Presenting in Tertiary Care Hospital. Esculapio - JSIMS
2025;21(01): 151-155
DOI: https://doi.org/10.51273/esc25.251321127
References
References
Tremblay D, Yacoub A, Hoffman R. Overview of
Myeloproliferative Neoplasms: History,
Pathogenesis, Diagnostic Criteria, and
Complications. Hematology/oncology clinics of
North America. 2021;35(2):159-76. DOI: 10.1016/
j.hoc.2020.12.001.
Pizzi M, Croci GA, Ruggeri M, Tabano S, Dei Tos AP,
Sabattini E, et al. The Classification of
Myeloproliferative Neoplasms: Rationale, Historical
Background and Future Perspectives with Focus on
Unclassifiable Cases. Cancers. 2021;13(22). DOI:
3390/cancers13225666.
Lin R, Tan YL. Myeloproliferative neoplasms:
Classifications and an approach to diagnosis.
Australian journal of general practice.
;50(9):622-7.
DOI: 10.31128/AJGP-03-21
Khanum F, Khanum A, Ahmad S. The Jak2 V617
Mutation Triggers Erythropoiesis And Patients
Presented With Good Hemoglobin Level In
Idiopathic Myelofibrosis (IMF). Esculapio Journal of
SIMS. 2023;9(1):15-6. https://esculapio.pk/journal/
index.php/journal-files/article/view/752.
Greenfield G, McMullin MF, Mills K. Molecular
pathogenesis of the myeloproliferative neoplasms.
J ournal of hematology & oncology.
;14(1):103.https://DOI.org/10.1186/s13045
-01116-z.
Karagianni A, Ravid K. Myeloproliferative disorders
and their effects on bone homeostasis: the role of
megakaryocytes. Blood. 2022;139(21):3127-37.
DOI: 10.1186/s13045-021-01116-z.
Ng ZY, Fuller KA, Mazza-Parton A, Erber WN.
Morphology of myeloproliferative neoplasms.
International journal of laboratory hematology.
;45 Suppl 2:59-70. DOI: 10.1111/ijlh.14086.
Nann D, Fend F. Synoptic Diagnostics of
Myeloproliferative Neoplasms: Morphology and
Molecular Genetics. Cancers. 2021;13(14). DOI:
3390/cancers13143528.
McMullin MF, Anderson LA. Aetiology of
Myeloproliferative Neoplasms. Cancers.
;12(7). DOI: 10.3390/cancers12071810.
Abdulnabi M, Al-Saadi EAKD. The Prevalence of
Myeloproliferative Disorders in A Group of Iraqi
Patients And Its Relation To Blood Indices
Parameters. Open Access Macedonian Journal of
Medical Sciences. 2020;8(A):660-5. https://
DOI.org/10.3889/oamjms.2020.5284.
Shashidhar MR, Kiran HS. A two years study of
showcasing the role of bone marrow aspiration in
diagnosing the spectrum of haematological disorders
in a tertiary care hospital. Journal of Evolution of
Medical and Dental Sciences. 2016;5:6594+.
DOI:10.14260/Jemds/2016/14910
Bao EL, Nandakumar SK, Liao X, Bick AG,
Karjalainen J, Tabaka M, et al. Inherited
myeloproliferative neoplasm risk affects
haematopoietic stem cells. Nature.
;586(7831):769-75. DOI: 10.1038/s41586-020
-7.
Mehta D, Theaker H, McLornan DP, Lambert J,
Wilson AJ, Ferreira H, et al. A Real World, Single
Centre Study of Young Adult Patients with
Philadelphia Negative Myeloproliferative
Neoplasms. Blood. 2023;142(Supplement 1):6402-.
https://DOI.org/10.1182/blood-2023-189502.
Noone AM, Cronin KA, Altekruse SF, Howlader N,
Lewis DR, Petkov VI, et al. Cancer Incidence and
Survival Trends by Subtype Using Data from the
Surveillance Epidemiology and End Results
Program, 1992-2013. Cancer epidemiology,
biomarkers & prevention : a publication of the
American Association for Cancer Research,
cosponsored by the American Society of Preventive
Oncology. 2017;26(4):632-41. DOI: 10.1158/1055
EPI-16-0520.
Hultcrantz M, Ravn Landtblom A, Andréasson B,
Samuelsson J, Dickman PW, Kristinsson SY, et al.
Incidence of myeloproliferative neoplasms - trends
by subgroup and age in a population-based study in
Sweden. Journal of internal medicine.
;287(4):448-54. DOI: 10.1111/joim.13019.
Memon FA, Memon AI, Pushpa NA, Nigar R, Ujjan I.
Clinico-Pathological Findings in Myeloid
Malignancies: A Single Center Experience. LUMHS
Journal of the Liaquat University of Medical Health
Sciences. 2017;16(1):49-52. DOI: 10.22442/
jlumhs.171610505.
Ümit E, Baysal M, Kırkızlar HO, Demir AM.
Myeloproliferative Neoplasm Symptom Assessment
Total Symptom Score (MPN-SAF TSS) in Chronic
Myeloproliferative Neoplasms, Related with Genetic
Burden, and Thrombosis. Turkish Journal of
Haematology: Official Journal of Turkish Society of
Haematology 2024. DOI: 10.4274/
tjh.galenos.2024.2024.0011.
Mesa RA, Niblack J, Wadleigh M, Verstovsek S,
Camoriano J, Barnes S, et al. The burden of fatigue
and quality of life in myeloproliferative disorders
(MPDs). 2007;109(1):68-76. DOI: 10.1002/
cncr.22365.
Moshetova LK, Egoryan LB, Vinogradova OJ,
Turkina KI, Shikhbabaeva DI. Contemporary
Interpretations of Ophthalmological Manifestations
of Chronic Myeloproliferative Neoplasms. Annals
RAMS. 2023;78(3):208-12 %J Annals RAMS.
https://DOI.org/10.15690/vramn2277.
Yunusova EM, Mukhamadeev TR, Bakirov BA.
Assessment of ocular manifestation frequency and
quality of life in chronic myeloproliferative
disorders. Bulletin of RSMU. 2022; (3): 83–7. DOI:
24075/brsmu.2022.027.
ZHANG Mengyu, Baomei, SHI Hongxia, Wait.
Clinical and genetic mutation characteristics of
young Chinese patients with myeloproliferative
neoplasms [J] . Chinese Journal of Hematology,
, 44(3) : 193-201. DOI: 10.3760/
cma.j.issn.0253-2727.2023.03.004
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Esculapio Journal of SIMS
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
